Evidence map›Paper›PMID 35508101›Full record

ArticleMultiple sclerosis and related disorders2022

Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders.

Alessandro Dinoto, Matteo Gastaldi, Raffaele Iorio, Sofia Marini, Valentina Damato, Antonio Farina, Marco Zoccarato, Elia Sechi, Francesca Pinna, Giorgia Teresa Maniscalco and 4 more

Open access · greenAbstract readLetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Neurological Adverse Reactions to SARS-CoV-2 Vaccines.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Alessandro DinotoNeurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Matteo GastaldiNeuroimmunology Laboratory, IRCCS Mondino Foundation, Pavia, Italy.
Raffaele IorioUOC Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy.
Sofia MariniUniversità Cattolica del Sacro Cuore, Rome, Italy.
Valentina DamatoDepartment of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy.
Antonio FarinaDepartment of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy.
Marco ZoccaratoUOC Neurologia O.S.A. - Azienda Ospedale Università Di Padova, Padua, Italy.
Elia SechiAzienda Ospedaliera Universitaria Sassari, Unit of Neurology, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Francesca PinnaDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Giorgia Teresa ManiscalcoNeurological Clinic and Stroke Unit, Multiple Sclerosis Center, "A. Cardarelli" Hospital, Naples, Italy.
Ruggero BarnabeiNeurology Unit, University of Pavia, Italy.
Luigi ZulianiNeurology Unit, AULSS8 Berica, Vicenza, Italy.
Sergio FerrariNeurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Sara MariottoNeurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. Electronic address: sara.mariotto@gmail.com.
University of Verona · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Florence · ITFondazione Istituto Neurologico Nazionale Casimiro Mondino · ITOspedale Antonio Cardarelli · ITUniversity of Cagliari · ITUniversity of Pavia · ITUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn this retrospective multicenter study, we evaluated the safety of SARS-CoV-2 vaccination in patients harboring autoantibodies targeting neuronal surface and/or synaptic antigens.

methodsFrom eight Italian Neurology Units, we included patients with: a) serum and/or CSF positivity for specific neuronal autoantibodies; b) a compatible neurological syndrome; and c) available follow-up ≥6 weeks after vaccination with any of the approved SARS-CoV-2 vaccines. Demographics, clinical data, and information regarding previous SARS-CoV-2 infection and vaccination were collected. Disease relapses were considered "post-infectious" or "post-vaccination" when occurring within 6 weeks from infection/vaccination.

resultsWe included 66 patients; 7/66 (11%) had a previous history of SARS-CoV-2 infection and 1/7 (14%) had post-infection relapses. BNT162b2-Pfizer-BioNTec was administered in 55 cases (83.3%) and mRNA-1273-Moderna in 11 (16.7%). The median number of doses administered per patient was 2 (1-3) and >50% of patients did not experience side effects. Five patients (8%) had post-vaccination relapses (seizure 3/5); 4/5 improved after immunotherapy, while one did not receive immunotherapy and worsened. Patients with post-vaccination relapses had higher disability scores at vaccination (p = 0.025), a trend favoring Leucine-rich glioma-inactivated protein 1 LGI1 glutamic acid decarboxylase 65 (GAD65) antibodies (p =  0.054) and shorter time from last relapse (p = 0.057). DISCUSSION: Our data support the safety of SARS-CoV-2 vaccines in patients with neurological disorders associated with antibodies to neuronal and synaptic antigens.

Indexed as

COVID-19Viral VaccinesAntibodies, ViralAutoantibodiesBNT162 VaccineCOVID-19 VaccinesHumansNeoplasm Recurrence, LocalSARS-CoV-2VaccinationAntibodies, ViralAutoantibodiesBNT162 VaccineCOVID-19 VaccinesViral VaccinesAutoimmune encephalitisCNS autoantibodiesSafetySARS-CoV-2Vaccination

Identifiers

PMID35508101
PMCPMC9035564
OpenAlexW4224326016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.